BlackRock’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-87,321
| Closed | -$1.66M | – | 5199 |
|
|
2019
Q1 | $1.66M | Buy |
87,321
+71,774
| +462% | +$1.16M | ﹤0.01% | 3768 |
|
|
2018
Q4 | $209K | Buy |
15,547
+14,547
| +1,455% | +$163K | ﹤0.01% | 4219 |
|
|
2018
Q3 | $11K | Buy |
+1,000
| New | +$10K | ﹤0.01% | 4721 |
|
|
2017
Q1 | – | Sell |
-2,068
| Closed | -$10K | – | 5156 |
|
|
2016
Q4 | $10K | Sell |
2,068
-272
| -12% | -$1.39K | ﹤0.01% | 3406 |
|
|
2016
Q3 | $12K | Sell |
2,340
-680
| -23% | -$3.48K | ﹤0.01% | 3381 |
|
|
2016
Q2 | $15K | Buy |
3,020
+2,366
| +362% | +$12.7K | ﹤0.01% | 3343 |
|
|
2016
Q1 | $4K | Buy |
654
+266
| +69% | +$1.86K | ﹤0.01% | 3399 |
|
|
2015
Q4 | $4K | Hold |
388
| – | – | ﹤0.01% | 3242 |
|
|
2015
Q3 | $7K | Hold |
388
| – | – | ﹤0.01% | 2923 |
|
|
2015
Q2 | $8K | Hold |
388
| – | – | ﹤0.01% | 2961 |
|
|
2015
Q1 | $7K | Hold |
388
| – | – | ﹤0.01% | 2961 |
|
|
2014
Q4 | $6K | Hold |
388
| – | – | ﹤0.01% | 3044 |
|
|
2014
Q3 | $5K | Hold |
388
| – | – | ﹤0.01% | 3113 |
|
|
2014
Q2 | $6K | Sell |
388
-106
| -21% | -$1.56K | ﹤0.01% | 3109 |
|
|
2014
Q1 | $6K | Hold |
494
| – | – | ﹤0.01% | 3038 |
|
|
2013
Q4 | $8K | Hold |
494
| – | – | ﹤0.01% | 2901 |
|
|
2013
Q3 | $8K | Sell |
494
-2,900
| -85% | -$42.9K | ﹤0.01% | 2836 |
|
|
2013
Q2 | $34K | Buy |
+3,394
| New | +$35.7K | ﹤0.01% | 2031 |
|
Other funds holding OSIR
BlackRock's OSIR Position: Q2 2019 in Review
BlackRock sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 87,321 shares — an estimated $1.66M sold.
BlackRock first reported a position in OSIR in Q2 2013 and held it in 18 quarters. The position peaked at $1.66M in Q1 2019. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.
- BlackRock reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
- BlackRock sold 87,321 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $1.66M.
- BlackRock first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
- BlackRock's Osiris Therapeutics, Inc. Common Stock position peaked at $1.66M in Q1 2019.
- 1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.
Based on BlackRock's 13F filing for Q2 2019, filed 13 Aug 2019.